AKA-388
Ruxolitinib Hemifumarate

Cat. No.

AKA-388

CAS No.

2803478-47-7

MF

C17H18N6.1/2C4H4O4

MW

728.80

Ruxolitinib Hemifumarate is a selective Janus kinase (JAK) 1 and JAK2 inhibitor belonging to the pyrrolopyrimidine class of compounds.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Service
Need help? Our team of experienced experts is here for you with full support.
86-28-85159085
info@aktin.com
Inquiry
Technical Data
Description
Storage and Shipping
References
Product Name
Ruxolitinib Hemifumarate
CAS No.
2803478-47-7
MF
 C17H18N6.1/2C4H4O4
MW
728.80
Specification
98.0%~102.0%
Documents
Certificate of Analysis (COA), API specification sheet, Safety Data Sheet (SDS/MSDS), evidence of GMP compliance, Stability data / Stability summary, etc.
Description
Ruxolitinib Hemifumarate is a selective Janus kinase (JAK) 1 and JAK2 inhibitor belonging to the pyrrolopyrimidine class of compounds.
Packing: 100g/bag,500g/bag,1kg/bag,5kg/bag 
Availability: In stock
API Current Development Status: A3---Process Development / Scale-Up
Reference: 
Aktin major API development processes:
A1.Feasibility / Route Development
A2.Laboratory Process Development
A3.Process Development / Scale-Up
A4.GMP Clinical Development
A5.Commercial GMP Supply
Storage and Shipping
Store under frozen or refrigerated conditions, keep away from strong light and heat.
References

[1].Lin Q, Meloni D, Pan Y, Xia M, Rodgers J, Shepard S, et al. Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction. Org Lett. 2009;11(9):1999-2002. doi:10.1021/ol900350k.

[2].Crystalline forms of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile salts and preparation thereof. International patent WO2017125097A1. 2017.

[3].Novel polymorph of ruxolitinib hemifumarate and method of preparation. International patent WO2024172778A1. 2024.

[4].Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-17. doi:10.1182/blood-2009-04-214957.

Disclaimer
The information provided on generic APIs is for general reference and market assessment purposes only. Regulatory status, market availability, specifications, patents, and commercial terms may vary by country and change over time. Users should independently verify all information with the relevant regulatory authorities and qualified professionals before making any regulatory, manufacturing, investment, or commercial decisions.
We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
AKA-387
Icotrokinra Hydrochloride

CAS No.:3049491-48-4

MF:C90H120N20O22S2.xHCl

View Details
AKA-386
Polymyxin B Sulfate

CAS No.: 1405-20-5

MF: C56H98N16O13(Free Base)

View Details
AKA-385
Sinomenine Hydrochloride

CAS No.:6080-33-7

MF:C19H24ClNO4

View Details
AKA-384
Tedizolid phosphate

CAS No.: 856867-55-5

MF:C17H16FN6O6P

View Details
AKA-383
Brivaracetam

CAS No.:357336-20-0

MF:C11H20N2O2

View Details
AKA-382
Cobimetinib Fumarate

CAS No.:1369665-02-0

MF:C46H46F6I2N6O8

View Details
AKA-379
Bempedoic acid

CAS No.:738606-46-7

MF:C19H36O5

View Details
AKA-378
Borofalan(10B)

CAS No.:80994-59-8

MF:C9H12BNO4

View Details
AKA-377
AkProva™ Metildigoxin

CAS No.:30685-43-9(acetone-free)

MF:C42H66O14.1/2C3H6O

View Details
AKA-376
AkProva™ beta-Acetyldigoxin

CAS No.:5355-48-6

MF:C43H66O15

View Details
* Some statements have not been evaluated by national authorities.
* Some products are not intended to diagnose, treat, cure, or prevent any disease.
* For literature supporting, please contact us directly.
Cart
TotalProducts
Request Quote
  • China
  • Afghanistan
  • Albania
  • Algeria
  • Andorra
  • Angola
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Brazil
  • Brunei
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Central African Republic
  • Chad
  • Chile
  • Colombia
  • Comoros
  • Congo (Brazzaville)
  • Congo (Kinshasa)
  • Cook Islands
  • Costa Rica
  • Côte d'Ivoire
  • Croatia
  • Cuba
  • Cyprus
  • Czech Republic
  • Denmark
  • Djibouti
  • Dominica
  • Dominican Republic
  • East Timor (Timor-Leste)
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Eswatini
  • Ethiopia
  • Fiji
  • Finland
  • France
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Greece
  • Grenada
  • Guatemala
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Honduras
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • South Korea
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Libya
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Mauritania
  • Mauritius
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Morocco
  • Mozambique
  • Myanmar (Burma)
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • North Macedonia
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Qatar
  • Romania
  • Russia
  • Rwanda
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Vincent and the Grenadines
  • Samoa
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • Spain
  • Sri Lanka
  • Sudan
  • South Sudan
  • Suriname
  • Sweden
  • Switzerland
  • Syria
  • Tajikistan
  • Tanzania
  • Thailand
  • Togo
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates (UAE)
  • United Kingdom (UK)
  • United States (US)
  • Uruguay
  • Uzbekistan
  • Vanuatu
  • Vatican City
  • Venezuela
  • Vietnam
  • Yemen
  • Zambia
  • Zimbabwe
  • Beijing-Beijing
  • Tianjin-Tianjin
  • Hebei-Shijiazhuang
  • Shanxi-Taiyuan
  • Inner Mongolia-Hohhot
  • Liaoning-Shenyang
  • Jilin-Changchun
  • Heilongjiang-Harbin
  • Shanghai-Shanghai
  • Jiangsu-Nanjing
  • Zhejiang-Hangzhou
  • Anhui-Hefei
  • Fujian-Fuzhou
  • Jiangxi-Nanchang
  • Shandong-Jinan
  • Henan-Zhengzhou
  • Hubei-Wuhan
  • Hunan-Changsha
  • Guangdong-Guangzhou
  • Guangxi-Nanning
  • Hainan-Haikou
  • Chongqing-Chongqing
  • Sichuan-Chengdu
  • Guizhou-Guiyang
  • Yunnan-Kunming
  • Tibet-Lhasa
  • Shaanxi-Xi'an
  • Gansu-Lanzhou
  • Qinghai-Xining
  • Ningxia-Yinchuan
  • Xinjiang-Urumqi
  • Hong Kong-Hong Kong
  • Macao-Macao
  • Taiwan-Taipei